Skip to main content
Top
Published in: Pediatric Nephrology 6/2004

01-06-2004 | Brief Report

Renoprotection by ACE inhibitors after severe hemolytic uremic syndrome

Authors: Maria Van Dyck, Willem Proesmans

Published in: Pediatric Nephrology | Issue 6/2004

Login to get access

Abstract

Five patients with severe hemolytic uremic syndrome (HUS) were followed for 10–18 years. Because of proteinuria, arterial hypertension, and reduced glomerular filtration rates, they received either captopril (n=2) or enalapril (n=3), or both (n=1) for 8–15 years. Blood pressure was normalized and proteinuria reduced in all; glomerular filtration improved in three patients and fell moderately in two. Four of the five patients have reached adult age with body weight and height, blood pressure, and serum creatinine levels within the normal range. At the last evaluation, median proteinuria was 220 mg/24 h (range 0–310) and glomerular filtration rate 56 ml/min per 1.73 m2 (range 40–127). This long-term study indicates a renoprotective effect of angiotensin-converting enzyme inhibitors in patients with sequelae after HUS.
Literature
1.
go back to reference Brenner BM (2002) Remission of renal disease: recounting the challenge, acquiring the goal. J Clin Invest 110:1753–1758CrossRefPubMed Brenner BM (2002) Remission of renal disease: recounting the challenge, acquiring the goal. J Clin Invest 110:1753–1758CrossRefPubMed
2.
go back to reference Kaplan BS, Proesmans W (1987) The hemolytic uremic syndrome of childhood and its variants. Semin Hematol 24:148–160PubMed Kaplan BS, Proesmans W (1987) The hemolytic uremic syndrome of childhood and its variants. Semin Hematol 24:148–160PubMed
3.
go back to reference Jafar TH, Schmid CH, Landa M, Giatras I, Toto R, Remuzzi G, Masschio G, Brenner BM, Kamper A, Zucchelli P, Becker G, Himmelmann A, Bannister K, Landais P, Shahinfar S, Jong PE de, Zeeuw D de, Lau J, Levey AS (2001) Angiotensin-converting enzyme inhibitors and progression of nondiabetic disease. A meta-analysis of patient-level data. Ann Intern Med 135:73–87PubMed Jafar TH, Schmid CH, Landa M, Giatras I, Toto R, Remuzzi G, Masschio G, Brenner BM, Kamper A, Zucchelli P, Becker G, Himmelmann A, Bannister K, Landais P, Shahinfar S, Jong PE de, Zeeuw D de, Lau J, Levey AS (2001) Angiotensin-converting enzyme inhibitors and progression of nondiabetic disease. A meta-analysis of patient-level data. Ann Intern Med 135:73–87PubMed
4.
go back to reference Monnens LAH, Donckerwolcke RAMG (1998) Nierziekten en hypertensie. In: Van den Brande JL, Heymans HSA, Monnens LAH (eds) Kindergeneeskunde, 3rd edn. Elsevier, pp 479–498 Monnens LAH, Donckerwolcke RAMG (1998) Nierziekten en hypertensie. In: Van den Brande JL, Heymans HSA, Monnens LAH (eds) Kindergeneeskunde, 3rd edn. Elsevier, pp 479–498
5.
go back to reference Cook J, Daneman D, Spino M, Sochett E, Perlman K, Balfe JW (1990) Angiotensin converting enzyme inhibitor therapy to decrease microalbuminuria in normotensive children with insulin-dependent diabetes mellitus. J Pediatr 117:39–45PubMed Cook J, Daneman D, Spino M, Sochett E, Perlman K, Balfe JW (1990) Angiotensin converting enzyme inhibitor therapy to decrease microalbuminuria in normotensive children with insulin-dependent diabetes mellitus. J Pediatr 117:39–45PubMed
6.
go back to reference Yüksel H, Darcan S, Kabasakal C, Cura A, Mir S, Mavi E (1998) Effect of enalapril on proteinuria, phosphaturia and calciuria in insulin-dependent diabetes. Pediatr Nephrol 12:648–650CrossRefPubMed Yüksel H, Darcan S, Kabasakal C, Cura A, Mir S, Mavi E (1998) Effect of enalapril on proteinuria, phosphaturia and calciuria in insulin-dependent diabetes. Pediatr Nephrol 12:648–650CrossRefPubMed
7.
go back to reference Proesmans W, Van Wambeke I, Van Dyck M (1996) Long-term therapy with enalapril in patients with nephrotic-range proteinuria. Pediatr Nephrol 10:587–589 Proesmans W, Van Wambeke I, Van Dyck M (1996) Long-term therapy with enalapril in patients with nephrotic-range proteinuria. Pediatr Nephrol 10:587–589
8.
go back to reference Delucchi A, Cano F, Rodriguez E, Wolff E, Gonzalez X, Cumsille MA (2000) Enalapril and prednisone in children with nephrotic-range proteinuria. Pediatr Nephrol 14:1088–1091CrossRefPubMed Delucchi A, Cano F, Rodriguez E, Wolff E, Gonzalez X, Cumsille MA (2000) Enalapril and prednisone in children with nephrotic-range proteinuria. Pediatr Nephrol 14:1088–1091CrossRefPubMed
9.
go back to reference Lama G, Salsano ME, Pedulla M, Grassia C, Ruocco G (1998) Angiotensin-converting enzyme inhibitors and reflux nephropathy: 2 year follow-up. Pediatr Nephrol 11:714–718CrossRef Lama G, Salsano ME, Pedulla M, Grassia C, Ruocco G (1998) Angiotensin-converting enzyme inhibitors and reflux nephropathy: 2 year follow-up. Pediatr Nephrol 11:714–718CrossRef
10.
go back to reference Proesmans W, Knockaert H, Trouet D (2000) Enalapril in pediatric patients with Alport syndrome: 2 years’ experience. Eur J Pediatr 159:430–433CrossRefPubMed Proesmans W, Knockaert H, Trouet D (2000) Enalapril in pediatric patients with Alport syndrome: 2 years’ experience. Eur J Pediatr 159:430–433CrossRefPubMed
11.
go back to reference Monnens L, Drayer J, De Jong M (1981) Malignant hypertension in a child with hemolytic uremic syndrome treated with captopril. Acta Paediatr Scand 70:583–585PubMed Monnens L, Drayer J, De Jong M (1981) Malignant hypertension in a child with hemolytic uremic syndrome treated with captopril. Acta Paediatr Scand 70:583–585PubMed
12.
go back to reference Griswold W, McNeal R, O’Connor D, Reznik V, Mendoza S (1982) Oral converting enzyme inhibitor in malignant hypertension. Arch Dis Child 57:235–237PubMed Griswold W, McNeal R, O’Connor D, Reznik V, Mendoza S (1982) Oral converting enzyme inhibitor in malignant hypertension. Arch Dis Child 57:235–237PubMed
13.
go back to reference Pennesi M, Torre G (2000) Angiotensin-converting enzyme inhibition in non-diabetic nephropathy with non-nephrotic proteinuria. Pediatr Nephrol 14:438PubMed Pennesi M, Torre G (2000) Angiotensin-converting enzyme inhibition in non-diabetic nephropathy with non-nephrotic proteinuria. Pediatr Nephrol 14:438PubMed
14.
go back to reference Wells T, Rippley R, Hogg R, Sakarcan A, Blowey D, Walson P, Vogt B, Delucchi A, Lo MW, Hand E, Panebianco D, Shaw W, Shahinfar S (2001) The pharmacokinetics of enalapril in children and infants with hypertension. J Clin Pharmacol 41:1064–1074PubMed Wells T, Rippley R, Hogg R, Sakarcan A, Blowey D, Walson P, Vogt B, Delucchi A, Lo MW, Hand E, Panebianco D, Shaw W, Shahinfar S (2001) The pharmacokinetics of enalapril in children and infants with hypertension. J Clin Pharmacol 41:1064–1074PubMed
Metadata
Title
Renoprotection by ACE inhibitors after severe hemolytic uremic syndrome
Authors
Maria Van Dyck
Willem Proesmans
Publication date
01-06-2004
Publisher
Springer-Verlag
Published in
Pediatric Nephrology / Issue 6/2004
Print ISSN: 0931-041X
Electronic ISSN: 1432-198X
DOI
https://doi.org/10.1007/s00467-004-1451-y

Other articles of this Issue 6/2004

Pediatric Nephrology 6/2004 Go to the issue